GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit's technology platform solves current delivery challenges by systematically screening its proprietary nanoparticle library and providing safer and efficient delivery to target tissues. GenEdit's proprietary nanoparticles has broad applicability including the development of CRISPR-based therapeutics and gene therapy products for a wide range of genetic diseases.